C. Nefazodone and trazodone

These drugs are weak inhibitors of serotonin reuptake. Their therapeutic benefit appears to be related to their ability to block postsynaptic 5-HT2A receptors. With chronic use, these agents may desensitize 5-HT1A presynaptic autoreceptors and, thereby, increase serotonin release. They are sedating, probably because of their potent H1-blocking activity. they are weak inhibitors of NE and 5-HT transporters their half-lives are short and usually require administration 2 or 3 times daily.